[Pregnancy nephropathies].
Our understanding of the pathophysiology underlying the hypertensive diseases of pregnancy has clearly progressed during the past ten years. The key phenomenon is an early defect of placentation occurring at the end of the first trimester and associated with a more widespread endothelial disorder. This results in early activation of the coagulation cascade and imbalance between prostacyclin and thromboxanes. Hypertension and proteinuria only occur after several weeks or months of placental dysfunction. This explains why antihypertensive treatments are ineffective in improving the prognosis of such pregnancies. In contrast, early preventive treatments, such as antiplatelet therapy, seem to be very promising for these patients. In this respect, early prediction of the risk associated with pregnancy has become a key goal.
Beaufils
M
M
Service de Médecine interne A, Hôpital Tenon, Paris.
Uzan
S
S
D000328:Adult; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D011464:Epoprostenol / Q000096:biosynthesis; D005260:Female; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000145:classification / Q000150:complications / Q000503:physiopathology* / Q000628:therapy; D007674:Kidney Diseases / Q000209:etiology*; D010927:Placental Insufficiency / Q000150:complications / Q000503:physiopathology* / Q000628:therapy; D011225:Pre-Eclampsia / Q000145:classification / Q000150:complications / Q000503:physiopathology* / Q000628:therapy; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000139:chemically induced / Q000628:therapy; D013928:Thromboxane A2 / Q000096:biosynthesis
D000959:Antihypertensive Agents; D013928:Thromboxane A2; D011464:Epoprostenol; D001241:Aspirin
Néphropathies gravidiques.